According to data updated in early September 2025 by the National Health Surveillance Agency (Anvisa), patients who choose the importation route currently have about 600 options of cannabis products. The information was disclosed through Technical Note No. 58/2025, which details the procedures for individual importation, according to RDC No. 660/2022.

See the complete table: Click here

This significant volume of options is only possible because the market already brings together more than 500 companies. Among them, Korasana stands out, leading with nine products, in addition to FoliuMed SAS, Levendis SAS, and FarmaUSA Pharmaceutical LLC, each with six items available. See the complete list: 

Origin and available formats

The listed products come from various countries, with the United States being the main supplier. Canada, Colombia, Uruguay, the Netherlands, Spain, and others also have a significant presence.

Most are marketed in the form of oils or tinctures, usually in milliliters (ml). However, the list also includes capsules, softgels, gummies, sprays, gels, creams, and even honey — demonstrating the diversity of available presentations for patients.

Formulations vary according to the concentration of cannabinoids (CBD, THC, or both), with indication by volume or unit. Common examples include "30ml / 1500-6000mg" or "30 capsules / 750mg". Among the items with higher THC content, one product stands out for containing up to 3,000mg of Delta 8, highlighting its high potency.

Limits and restrictions by Anvisa

According to the Technical Note, some products will have their registration approved automatically, while others will depend on technical analysis. Anvisa emphasizes that these items are not registered in Brazil and have not been evaluated for efficacy, quality, or safety. Therefore, authorization occurs on an exceptional basis, often supported by court decisions.

Another point highlighted is that such products cannot be considered medicines. Importation, storage, distribution, or resale by companies are prohibited, with importation only allowed for individuals, for personal and non-transferable use.

In addition, the importation of cannabis flowers in natura, plant parts, or concentrated extracts intended for smoking remains prohibited.

What is RDC 660?

The Resolution of the Collegiate Board of Directors (RDC) 660, created in March 2022, established criteria for patients to import cannabis-based products not yet regulated in Brazil.

The measure expanded access to a more diversified portfolio, with different concentrations in milligrams per milliliter, providing better cost-benefit for patients.

Impacts of RDC 660 on the sector

The regulation also helped organize the market. As highlighted by Paula Scanapieco, commercial manager of Mile Express, RDC 660 "ended a lot of wrong things" by requiring documentary and regulatory compliance.

For her, who participated in the Deusa Cast - Sechat Original Podcast, the resolution forced the sector to adapt to pharmaceutical standards, prioritizing seriousness, trusted partnerships, and transparency in processes.

According to experts, this movement contributes to the consolidation of a safer and more mature market, aligned with the needs of patients and the rigor of health legislation.

See the full episode: